Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis

American Journal of Kidney Diseases

Volumn 40, Issue 3, 2002, Pages 531-538

  Hainer, James W ^a,b,c,d,e   Sherrard, Donald J ^a,b,c,d,e   Swan, Suzanne K ^a,b,c,d,e   Barrett, Jeffrey S ^a,b,c,d,e   Assaid, Christopher A ^a,b,c,d,e   Fossler, Michael J ^a,b,c,d,e   Cox, Donna S ^a,b,c,d,e   Williams, Robert M ^a,b,c,d,e   Pittenger, Amy L ^a,b,c,d,e   Stephenson, Carol A ^a,b,c,d,e   Hua, Tsushung A ^a,b,c,d,e  

^a BRISTOL MYERS SQUIBB   (United States)

^b Veterans Administration   (United States)

^c Northwest Kidney Centers   (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

^e DAVITA CLINICAL RESEARCH   (United States)

Author keywords

Anti factor Xa (anti Xa); Anticoagulation; Deep vein thrombosis (DVT); End stage renal disease (ESRD); Hemodialysis (HD); Innohep; Low molecular weight heparin (LMWH); Pharmacodynamics; Pharmacokinetics; Renal failure; Thromboprophylaxis; Tinzaparin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE CALCULATION; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; PROSPECTIVE STUDY; THROMBOSIS; THROMBOSIS PREVENTION; VASCULAR ACCESS;

EID: 0036723925     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.34911     Document Type: Article

References (26)

1. Thrombosis and hemostasis in renal disease
2. Practical aspects of anticoagulant therapy
3. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and agratroban
4. Monitoring of low-molecular-weight heparins in cardiovascular disease
5. Factor Xa inhibition: Correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage
6. Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients
7. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease
8. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)
9. Production and chemical processing of low molecular weight heparins
10. Dose finding study of a low molecular weight heparin, innohep®, in haemodialysis
11. Pharmacokinetics of a low molecular weight heparin, Logiparin, after intravenous and subcutaneous administration to healthy volunteers
12. Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers
13. Elderly patients treated with tinzaparin (Innohep®) administered once daily (175 anti-Xa IU/kg): Anti-Xa and anti-IIa activities over 10 days
14. Enoxaparin pharmacokinetics and pharmacodynamics in renal impairment
15. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation
16. Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis
17. Long-term use of the low molecular weight heparin tinzaparin in haemodialysis
18. Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins
19. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation
20. Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency
21. Low-molecular-weight heparins: Pharmacologic profile and product differentiation
22. Vascular calcification in chronic renal failure